279 related articles for article (PubMed ID: 17173053)
1. The influence of cyclosporin alone, or cyclosporin and methotrexate, on the incidence of mixed haematopoietic chimaerism following allogeneic sibling bone marrow transplantation for severe aplastic anaemia.
McCann S; Passweg J; Bacigalupo A; Locasciulli A; Locatelli F; Ryan J; Schrezenmeier H; Lawler M
Bone Marrow Transplant; 2007 Jan; 39(2):109-14. PubMed ID: 17173053
[TBL] [Abstract][Full Text] [Related]
2. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA.
Lawler M; McCann SR; Marsh JC; Ljungman P; Hows J; Vandenberghe E; O'Riordan J; Locasciulli A; Socié G; Kelly A; Schrezenmeier H; Marin P; Tichelli A; Passweg JR; Dickenson A; Ryan J; Bacigalupo A;
Br J Haematol; 2009 Mar; 144(6):933-45. PubMed ID: 19183198
[TBL] [Abstract][Full Text] [Related]
3. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients.
Kim HJ; Park CY; Park YH; Kim YJ; Kim DW; Min WS; Kim CC
Bone Marrow Transplant; 2003 Jan; 31(2):79-86. PubMed ID: 12621487
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial.
Locatelli F; Bruno B; Zecca M; Van-Lint MT; McCann S; Arcese W; Dallorso S; Di Bartolomeo P; Fagioli F; Locasciulli A; Lawler M; Bacigalupo A
Blood; 2000 Sep; 96(5):1690-7. PubMed ID: 10961865
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis.
Yagasaki H; Kojima S; Yabe H; Kato K; Kigasawa H; Sakamaki H; Tsuchida M; Kato S; Kawase T; Muramatsu H; Morishima Y; Kodera Y
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1603-8. PubMed ID: 19896085
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A
Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants.
Hoyt R; Ritchie DS; Roberts AW; Macgregor L; Curtis DJ; Szer J; Grigg AP
Bone Marrow Transplant; 2008 Apr; 41(7):651-8. PubMed ID: 18176619
[TBL] [Abstract][Full Text] [Related]
8. [Favorable current prognosis after HLA-identical bone marrow transplantation for children with required severe aplastic anemia; evaluation of 30 years of bone marrow transplantation at the Leiden University Medical Center].
van Steekelenburg M; van Weel-Sipman MH; Zwinderman AH; Hoogerbrugge PM; Vossen JM; Egeler RM
Ned Tijdschr Geneeskd; 2002 Aug; 146(33):1542-6. PubMed ID: 12212502
[TBL] [Abstract][Full Text] [Related]
9. CsA-based post-graft immunosuppression: the main factor for improving outcome of allografted patients with acquired aplastic anemia. A retrospective survey by the Spanish Group of Hematopoietic Transplantation.
Arranz R; Conde E; Rodriguez-Salvanés F; Pajuelo FJ; Cabrera R; Sanz MA; Petit J; Bueno J; Maldonado J; Odriozola J; Conde JG; Brunet S; Carreras E; Iriondo A; Fernández-Rañada JM; Marín P;
Bone Marrow Transplant; 2002 Feb; 29(3):205-11. PubMed ID: 11859392
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
[TBL] [Abstract][Full Text] [Related]
11. Successful bone marrow transplantation in sensitized aplastic anemia patients using total lymphoid irradiation for conditioning: long-term follow-up.
Zapatero A; Marín A; López M; Martín De Vidales C; Cerezo L; Domínguez P; Pérez Torrubia A
Hematol Oncol; 1996 Dec; 14(4):165-72. PubMed ID: 9267462
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up.
Kahl C; Leisenring W; Deeg HJ; Chauncey TR; Flowers ME; Martin PJ; Sanders JE; Storb R
Br J Haematol; 2005 Sep; 130(5):747-51. PubMed ID: 16115132
[TBL] [Abstract][Full Text] [Related]
13. Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens.
Michallet AS; Fürst S; Le QH; Dubois V; Praire A; Nicolini F; Thomas X; Rafii H; Gebuhrer L; Michallet M
Br J Haematol; 2005 Mar; 128(5):676-89. PubMed ID: 15725090
[TBL] [Abstract][Full Text] [Related]
14. Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors.
Hamblin M; Marsh JC; Lawler M; McCann SR; Wickham N; Dunlop L; Ball S; Davies EG; Hale G; Waldmann H; Gordon-Smith EC
Bone Marrow Transplant; 1996 May; 17(5):819-24. PubMed ID: 8733704
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
Koga Y; Nagatoshi Y; Kawano Y; Okamura J
Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
[TBL] [Abstract][Full Text] [Related]
16. A systematic approach to molecular quantitative determination of mixed chimaerism following allogeneic bone marrow transplantation: an analysis of its applicability in a group of patients with severe aplastic anaemia.
Hassan R; Bonamino MH; Braggio E; Lobo AM; Seuánez HN; Tabak DG; Zalcberg IR
Eur J Haematol; 2004 Sep; 73(3):156-61. PubMed ID: 15287911
[TBL] [Abstract][Full Text] [Related]
17. Human leucocyte antigen-identical haematopoietic stem cell transplantation in major histocompatiblity complex class II immunodeficiency: reduced survival correlates with an increased incidence of acute graft-versus-host disease and pre-existing viral infections.
Renella R; Picard C; Neven B; Ouachée-Chardin M; Casanova JL; Le Deist F; Cavazzana-Calvo M; Blanche S; Fischer A
Br J Haematol; 2006 Sep; 134(5):510-6. PubMed ID: 16848795
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia.
George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
Bone Marrow Transplant; 2007 Jul; 40(1):13-8. PubMed ID: 17450183
[TBL] [Abstract][Full Text] [Related]
19. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
20. Low mortality of children undergoing hematopoietic stem cell transplantation from 7 to 8/10 human leukocyte antigen allele-matched unrelated donors with the use of antithymocyte globulin.
Sedlácek P; Formánková R; Keslová P; Srámková L; Hubácek P; Król L; Kulich M; Starý J
Bone Marrow Transplant; 2006 Dec; 38(11):745-50. PubMed ID: 17041606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
